UA120286C2 - Біспецифічне антитіло проти cd3 і cd20 - Google Patents

Біспецифічне антитіло проти cd3 і cd20 Download PDF

Info

Publication number
UA120286C2
UA120286C2 UAA201708112A UAA201708112A UA120286C2 UA 120286 C2 UA120286 C2 UA 120286C2 UA A201708112 A UAA201708112 A UA A201708112A UA A201708112 A UAA201708112 A UA A201708112A UA 120286 C2 UA120286 C2 UA 120286C2
Authority
UA
Ukraine
Prior art keywords
represented
sequence
amino acid
zeo
variable region
Prior art date
Application number
UAA201708112A
Other languages
English (en)
Ukrainian (uk)
Inventor
Патрік Енґелбертс
Патрик Энгелбертс
Естер Брей
Эстер Брей
Рік Радемакер
Рик Радемакер
Ізіл Алтінтас
Изил Алтинтас
Давід Сатейн
Давид Сатейн
Сандра Верплуґен
Сандра Верплуген
Рімке ван Дейкхейзен Радерсма
Римке ван Дейкхейзен Радерсма
ден Брінк Едвард ван
Ден Бринк Эдвард Ван
Яніне Схюірман
Янине Схюирман
Паул Паррен
Original Assignee
Ґенмаб А/С
Генмаб А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56355550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA120286(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2015/050276 external-priority patent/WO2015104346A1/en
Application filed by Ґенмаб А/С, Генмаб А/С filed Critical Ґенмаб А/С
Publication of UA120286C2 publication Critical patent/UA120286C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
UAA201708112A 2015-01-08 2016-01-08 Біспецифічне антитіло проти cd3 і cd20 UA120286C2 (uk)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/EP2015/050276 WO2015104346A1 (en) 2014-01-09 2015-01-08 Humanized or chimeric cd3 antibodies
DKPA201500412 2015-07-15
DKPA201500413 2015-07-15
DKPA201500415 2015-07-16
DKPA201500416 2015-07-16
PCT/EP2016/050296 WO2016110576A1 (en) 2015-01-08 2016-01-08 Bispecific antibodies against cd3 and cd20

Publications (1)

Publication Number Publication Date
UA120286C2 true UA120286C2 (uk) 2019-11-11

Family

ID=56355550

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201708112A UA120286C2 (uk) 2015-01-08 2016-01-08 Біспецифічне антитіло проти cd3 і cd20

Country Status (13)

Country Link
US (2) US10544220B2 (enExample)
EP (2) EP3242682A1 (enExample)
JP (3) JP6853176B2 (enExample)
KR (3) KR102663073B1 (enExample)
CN (2) CN107660214B (enExample)
AU (3) AU2016205967B2 (enExample)
CA (1) CA2973159A1 (enExample)
EA (1) EA201791554A1 (enExample)
IL (3) IL289946B2 (enExample)
MX (2) MX391279B (enExample)
SG (1) SG11201705496SA (enExample)
UA (1) UA120286C2 (enExample)
WO (1) WO2016110576A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
ES2776706T3 (es) 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
AU2015314744A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
PT3310814T (pt) 2015-06-16 2023-10-02 H Hoffnabb La Roche Ag Anticorpos humanizados e de afinidade amadurecida para fcrh5 e métodos de utilização
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
WO2017009442A1 (en) 2015-07-15 2017-01-19 Genmab A/S Humanized or chimeric cd3 antibodies
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AU2018276419A1 (en) * 2016-06-02 2019-10-17 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
EP3252078A1 (en) * 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
JP7083820B2 (ja) 2016-09-30 2022-06-13 セントレ ナショナル デ ラ レセルシュ シャンティフィク 膜マーカー
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CN113896797B (zh) 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
KR102758346B1 (ko) * 2017-08-04 2025-01-24 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
CN107501412A (zh) * 2017-10-11 2017-12-22 深圳精准医疗科技有限公司 突变型双特异性抗体及其应用
MA51793A (fr) 2018-02-08 2020-12-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
CN111787948A (zh) * 2018-02-09 2020-10-16 健玛保 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
EP3569617A1 (en) * 2018-05-18 2019-11-20 Trion Research GmbH Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109836502B (zh) * 2018-11-12 2021-09-07 浙江大学 一种双特异性抗体及其应用
WO2020159918A2 (en) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CA3131036A1 (en) * 2019-02-22 2020-08-27 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen-binding fragment and application thereof
JP7273195B2 (ja) * 2019-05-13 2023-05-12 エフ． ホフマン－ラ ロシュ アーゲー 干渉抑制薬物動態イムノアッセイ
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
AU2020328195A1 (en) * 2019-08-15 2022-03-03 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses
CN111100204B (zh) * 2019-11-26 2022-03-11 山东立菲生物产业有限公司 靶向cd20的抗体、其制备方法和应用
TWI897903B (zh) 2019-12-13 2025-09-21 美商建南德克公司 抗ly6g6d抗體及其使用方法
JP2023509991A (ja) * 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． 抗体及び免疫細胞エンゲージャーのコンジュゲート
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
AU2021236906A1 (en) 2020-03-18 2022-08-18 Genmab A/S Antibodies binding to B7H4
JP2023524149A (ja) * 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
US11976120B2 (en) 2020-06-01 2024-05-07 Boehringer Ingelheim International Gmbh Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
US10981996B1 (en) * 2020-06-01 2021-04-20 Abexxa Biologics, Inc. Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
AU2021342342A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
CA3192251A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
KR20230066391A (ko) * 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
US20230312758A1 (en) 2020-09-10 2023-10-05 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
CA3192255A1 (en) * 2020-09-10 2022-03-17 Brian Elliott Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
JP2023542092A (ja) * 2020-09-10 2023-10-05 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
US20240139322A1 (en) * 2021-03-10 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods to reduce therapeutic t cell toxicity
MX2023010567A (es) * 2021-03-12 2023-09-21 Genmab As Variantes de anticuerpos no activadoras.
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
MX2024008832A (es) 2022-01-28 2024-07-25 Genmab As Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
JP2025503176A (ja) 2022-01-28 2025-01-30 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
US11958906B2 (en) 2022-04-13 2024-04-16 Genentech, Inc. Pharmaceutical compositions of mosunetuzumab and methods of use
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
AU2023398887A1 (en) * 2022-12-14 2025-06-26 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma
AU2024255174A1 (en) 2023-04-13 2025-10-09 Genmab A/S Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
TW202509073A (zh) 2023-05-15 2025-03-01 丹麥商珍美寶股份有限公司 高度純化之依可利單抗組成物
TW202508630A (zh) 2023-05-15 2025-03-01 丹麥商珍美寶股份有限公司 治療表現ｃｄ２０之ｂ細胞癌症之方法
WO2025064890A1 (en) * 2023-09-20 2025-03-27 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
WO2025109119A1 (en) * 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05004022A (es) * 2002-10-17 2005-10-05 Genmab As Anticuerpos monoclonales humanos contra cd20.
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US20100325744A1 (en) 2007-05-31 2010-12-23 Genmab A/S Non-glycosylated recombinant monovalent antibodies
WO2008145141A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
US9322035B2 (en) 2007-05-31 2016-04-26 Genmab A/S Recombinant IgG4 monovalent antibodies
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
JP6040148B2 (ja) * 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
SG190726A1 (en) * 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
US20140170149A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
UA115402C2 (uk) 2011-05-21 2017-10-25 Макродженікс, Інк. Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
RS56879B1 (sr) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP2016512421A (ja) 2013-02-26 2016-04-28 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
ES2776706T3 (es) 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
EP3019622A4 (en) * 2013-07-12 2017-06-14 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding contructs
JP6449295B2 (ja) * 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
WO2017210485A1 (en) 2016-06-01 2017-12-07 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
WO2019034580A1 (en) * 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
KR20230066391A (ko) * 2020-09-10 2023-05-15 젠맵 에이/에스 여포성 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체

Also Published As

Publication number Publication date
JP6853176B2 (ja) 2021-03-31
IL289946A (en) 2022-03-01
CN114478792A (zh) 2022-05-13
NZ733531A (en) 2024-11-29
MX391279B (es) 2025-03-21
EP3242682A1 (en) 2017-11-15
MX2017008875A (es) 2017-09-27
KR102663073B1 (ko) 2024-05-07
KR20240064746A (ko) 2024-05-13
SG11201705496SA (en) 2017-08-30
KR102712786B1 (ko) 2024-10-04
IL318350A (en) 2025-03-01
AU2016205967B2 (en) 2021-11-11
KR20170128222A (ko) 2017-11-22
MX2022004082A (es) 2022-05-03
AU2022200871B2 (en) 2025-05-08
JP2023002615A (ja) 2023-01-10
EA201791554A1 (ru) 2017-12-29
CN107660214B (zh) 2022-02-08
IL253166B (en) 2022-02-01
JP7177317B2 (ja) 2022-11-24
WO2016110576A1 (en) 2016-07-14
IL253166A0 (en) 2017-08-31
JP2018508188A (ja) 2018-03-29
KR20240148942A (ko) 2024-10-11
US20200199231A1 (en) 2020-06-25
AU2022200871A1 (en) 2022-03-03
IL289946B1 (en) 2025-02-01
IL289946B2 (en) 2025-06-01
JP7596342B2 (ja) 2024-12-09
JP2021104020A (ja) 2021-07-26
US20170355767A1 (en) 2017-12-14
US10544220B2 (en) 2020-01-28
CN107660214A (zh) 2018-02-02
AU2016205967A1 (en) 2017-07-27
EP4678661A2 (en) 2026-01-14
BR112017014551A2 (pt) 2018-05-15
AU2025213616A1 (en) 2025-08-21
CA2973159A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
UA120286C2 (uk) Біспецифічне антитіло проти cd3 і cd20
JP7351533B2 (ja) 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
UA124631C2 (uk) Антитіло до pd-1
JP2021121208A (ja) 改変ｔ細胞に関する方法および組成物
UA126964C2 (uk) Конструкція біспецифічного антитіла, що зв'язується з дпб3 (dll3) і кд3 (cd3)
UA125818C2 (uk) Химерні рецептори антигенів на основі однодоменних антитіл і способи їх застосування
JP2022031906A (ja) 治療用細胞の活性化及び排除のための二重コントロール
UA128304C2 (uk) Мультиспецифічне антитіло до cd40 і cd137
UA127200C2 (uk) Молекула антитіла до pd1
UA125382C2 (uk) Антитіла проти людського vista та їх застосування
UA129471C2 (uk) Білки, які містять антигензв'язувальні домени пов'язаної з калікреїном пептидази 2, і їх застосування
UA128387C2 (uk) Антитіло до lag3
UA125611C2 (uk) Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
UA123104C2 (uk) Піролобензодіазепінові кон'югати антитіло-лікарський засіб і способи їх застосування
UA124615C2 (uk) АНТИТІЛО ПРОТИ ПОДІБНОГО ДО Fc-РЕЦЕПТОРА БІЛКА 5 (FcRH5)
UA114883C2 (uk) Антитіло до рецептора епідермального фактора росту-3 (her3)
UA124734C2 (uk) Антитіло проти с5 і його застосування
UA124417C2 (uk) БІСПЕЦИФІЧНИЙ КОНСТРУКТ АНТИТІЛА, ЩО ЗВ'ЯЗУЄ EGFRvIII І CD3
UA126280C2 (uk) Біспецифічні конструкції антитіл, які залучають т-клітини
UA127450C2 (uk) Рекомбінантний поліпептид, що зв'язується з cd123
UA122676C2 (uk) Біспецифічна антигензв'язувальна молекула проти folr1 і cd3, що активує t-клітини
UA119646C2 (uk) Гуманізоване антитіло, що зв`язується з сd3 людини
UA125718C2 (uk) Композиції антитіл до ror1 і пов'язані з ними способи
IL300420B2 (en) Compositions and methods for inhibition of lineage specific antigens
UA125898C2 (uk) Антитіла до tigit